Last reviewed · How we verify
Lixisenatide (AVE0010)
Lixisenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.
Lixisenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Lixisenatide (AVE0010) |
|---|---|
| Also known as | Lyxumia, Lyxumia®, Device: Disposable self-injector prefilled pen (Delta 14®) |
| Sponsor | Sanofi |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Lixisenatide binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, leading to reduced postprandial glucose excursions. These combined effects improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Headache
Key clinical trials
- Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes (PHASE4)
- The Effect of Lixisenatide on the Effect of Pituitary Hormones (PHASE4)
- Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (NA)
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin (PHASE3)
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (PHASE3)
- A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) (PHASE3)
- Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |